<DOC>
	<DOCNO>NCT00177814</DOCNO>
	<brief_summary>The propose endpoint study would : comparative use piperacillin versus broad spectrum agent ( e.g. , piperacillin/tazobactam , etc . ) [ measure define daily dos per 1000 patient day ] ; physician acceptance piperacillin part streamline program [ measure successful occurrence use piperacillin streamline therapy ] ; change susceptibility pattern broad spectrum antibiotic [ measure % Gram negative bacillus susceptible commonly use broad spectrum antibiotic ] ; outcome patient treat streamlined therapy .</brief_summary>
	<brief_title>Piperacillin Part Antibiotic Streamlining Intensive Care Unit</brief_title>
	<detailed_description>The following variable follow : time location positive culture , underlie disease severity illness , recent immunomodulative therapy , physical exam finding , laboratory radiographical data , antimicrobial usage , microbiological data resistance pattern , choice antibiotic organism identify , suspect source infection , bacteriological outcome , laboratory result , demographic information , medication , clinical outcome , gender , height , weight , ethnicity , past medical history .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<criteria>Patients Gram negative infection treat piperacillin/tazobactam and/or piperacillin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>pipercillin</keyword>
	<keyword>gram negative bacteria infection</keyword>
</DOC>